梯瓦制药 TEVA 深沪

交易中 10-06 10:14:33 美东时间

39.595

-0.055

-0.14%

华盛通

立即下载

最高40.79
今开39.66
成交量 43.31万股
最低 35.42
昨收 39.65
总市值 4395.05万
52周最高 40.79
市盈率 ^静 105.11
换手率 39.02%
52周最低 18.825
委比 71.43%
总股本 0.01亿
历史最高 69.8535
量比 1.23
振幅 13.54%
历史最低 6.07
每手 1
风险率 5.15%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

Teva Priced Approximately $4.9B (Equivalent) of Senior Notes

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) ("Teva") announced today that it successfully priced its offering of approximately $4.9 billion (equivalent) of senior notes (the "Notes"). Teva

09-10 18:10
Teva Reports Early Skin Repigmentation Data, Sets Stage For Next Trial

Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.

07-08 02:21
Teva Signals Confidence With $700 Million Pipeline Push, Buyback Plan

Teva to acquire Emalex for $700 million, posts Q1 earnings beat, and maintains 2026 outlook amid margin and buyback plans.

04-30 01:52
FDA Takes Step Forward on Testosterone Therapy for Men

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

04-16 23:37
Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda

Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.

04-02 01:36
What's Driving the Market Sentiment Around Teva Pharmaceutical Industries Ltd?

Teva Pharmaceutical Industries Ltd's (NYSE:TEVA) short interest as a percent of...

03-02 21:00
FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

FDA accepts Teva's application for the monthly schizophrenia injection TEV-749 as shares show mixed momentum signals.

02-23 21:48
Corcept Therapeutics Stock Plunges As Court Clears Teva Generic

Corcept Therapeutics shares plunged Thursday morning after a federal appeals court upheld a ruling that Teva Pharmaceuticals' proposed generic does not infringe two Korlym-related patents.

02-20 00:48
Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and celiac disease, with new trial results expected in 2026.

01-13 01:26
Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift

S&P upgraded Teva to BB+ and Moody's turned positive, citing falling leverage, stronger cash flow, and branded drug momentum that could support a future investment-grade rating.

2025-12-24 22:51

派息除权日	每股总股息	派息日期
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-20	0.04	1991-09-19
1991-05-19	0.04	1991-07-19
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-16	0.04	1990-09-17
1989-05-21	0.04	1989-06-18
1988-12-06	0.04	1988-12-30
1988-09-07	0.04	1988-10-05
1988-06-09	0.03	1988-07-19
1988-04-12	0.03	1988-05-15
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-08	0.04	1987-08-04
1987-06-21	0.03	1987-07-13
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名称	梯瓦制药
行业分类	制药
业务描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦制药 TEVA 深 沪

39.595

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

梯瓦制药 TEVA 深沪